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Abstract
Background: Recombinant human growth hormone (rhGH) reduces visceral adipose tissue (VAT) volume in HIV-infected
patients but can worsen glucose homeostasis and lipoatrophy. We aimed to determine if adding rosiglitazone to rhGH
would abrogate the adverse effects of rhGH on insulin sensitivity (SI) and subcutaneous adipose tissue (SAT) volume.
Methodology/Principal Findings: Randomized, double-blind, placebo-controlled, multicenter trial using a 262 factorial
design in which HIV-infected subjects with abdominal obesity and insulin resistance were randomized to rhGH 3 mg daily,
rosiglitazone 4 mg twice daily, combination rhGH + rosiglitazone, or double placebo (control) for 12 weeks. The primary
endpoint was change in SI by frequently sampled intravenous glucose tolerance test from entry to week 12. Body
composition was assessed by whole body magnetic resonance imaging (MRI) and dual Xray absorptiometry
(DEXA). Seventy-seven subjects were randomized of whom 72 initiated study drugs. Change in SI from entry to week
12 differed across the 4 arms by 1-way ANCOVA (P = 0.02); by pair-wise comparisons, only rhGH (decreasing SI; P = 0.03)
differed significantly from control. Changes from entry to week 12 in fasting glucose and glucose area under the curve on 2-
hour oral glucose tolerance test differed across arms (1-way ANCOVA P = 0.004), increasing in the rhGH arm relative to
control. VAT decreased significantly in the rhGH arms (217.5% in rhGH/rosiglitazone and 222.7% in rhGH) but not in the
rosiglitazone alone (22.5%) or control arms (21.9%). SAT did not change significantly in any arm. DEXA results were
consistent with the MRI data. There was no significant rhGH x rosiglitazone interaction for any body composition parameter.
Conclusions/Significance: The addition of rosiglitazone abrogated the adverse effects of rhGH on insulin sensitivity and
glucose tolerance while not significantly modifying the lowering effect of rhGH on VAT.
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Introduction
Altered fat distribution is prevalent among HIV-infected
patients receiving antiretroviral therapy and can consist of loss of
subcutaneous fat (lipoatrophy), gain of fat predominantly in the
visceral depot (lipohypertrophy), or a combination of both [1,2].
While lipoatrophy has been attributed to mitochondrial toxicity
from thymidine analogue reverse transcriptase inhibitors [3], the
pathogenesis of lipohypertrophy is poorly understood. Initiation of
contemporary antiretroviral regimens that avoid thymidine
analogues is associated with increases in visceral fat but
uncommonly with loss of subcutaneous fat [4].
Some HIV-infected patients with altered fat distribution have
decreased endogenous pulsatile growth hormone secretion that is
inversely proportional to the amount of visceral fat [5,6].
Administration of supraphysiologic doses of recombinant human
growth hormone (rhGH) reduces visceral fat in HIV-infected
patients with lipohypertrophy [7–10], but its use is limited by
toxicities including adverse effects on glucose homeostasis.
Although insulin resistance is common in HIV-infected patients
with abdominal obesity, pivotal trials of rhGH excluded subjects
with impaired glucose tolerance and diabetes mellitus [8,9].
Though somewhat selective for visceral fat, administration of
rhGH may also reduce subcutaneous fat modestly [8–10], which is
an undesirable effect in patients with co-existing lipoatrophy.
Thiazolidinediones are peroxisome proliferator activator-c
agonists that improve insulin sensitivity and increase differentia-
tion of pre-adipocytes into adipocytes [11]. While data are
conflicting, rosiglitazone and pioglitazone may increase subcuta-
neous fat in HIV-infected patients who are not taking thymidine
analogue drugs [12,13]. We hypothesized that co-administration
of rosiglitazone with rhGH to HIV-infected patients with
lipohypertrophy and insulin resistance would abrogate the adverse
effects of rhGH on insulin sensitivity and subcutaneous fat. To test
this hypothesis, we conducted a randomized, double-blinded,




The protocol for this trial and supporting CONSORT checklist
are available as supplementary information; see Protocol S1 and
Checklist S1. This was a randomized, double-blind, placebo-
controlled, multicenter trial using a 262 factorial design. Eligible
subjects were randomized in a 1:1:1:1 ratio to receive recombinant
human growth hormone (rhGH), rosiglitazone, rhGH + rosiglita-
zone, or double placebo treatment for 12 weeks.
The primary endpoint was the change in insulin sensitivity
index (SI) from baseline to week 12 assessed by frequently sampled
intravenous glucose tolerance test (FSIVGTT). Key secondary
endpoints included changes from baseline to week 12 in visceral
adipose tissue (VAT) and subcutaneous adipose tissue (SAT)
volumes by magnetic resonance imaging (MRI) and total and
regional fat mass by dual energy X-ray absorptiometry (DEXA).
Participants
Eligible subjects were 18 to 65 years old with documented HIV-
1 infection and on stable antiretroviral medications for at least 8
weeks. They had to meet established anthropometric criteria for
excess abdominal fat consisting of both waist circumference
.88.2 cm for men and 75.3 cm for women and waist:hip ratio
$0.95 cm for men and $0.90 for women [14,15]. They also had
to have evidence of insulin resistance based on a quantitative
insulin sensitivity check index [16] (QUICKI)#0.33. Subjects had
to weigh .36 kg and have liver transaminase values #2.5 times
the upper limit of normal, fasting glucose #6.94 mmol/L
(125 mg/dL), two-hour glucose ,11.1 mmol/L (200 mg/dL) on
oral glucose tolerance test (OGTT), and fasting triglycerides
#8.48 mmol/L (750 mg/dL). Subjects with active malignancy or
systemic infection, prior diagnosis of pancreatitis, carpal tunnel
syndrome, prior diagnosis of diabetes mellitus, coronary artery
disease, disorder associated with moderate to severe edema, and
untreated or uncontrolled hypertension, or contraindication to
MRI were excluded. Subjects were permitted to use lipid lowering
agents and testosterone therapy for hypogonadism (but no other
androgenic/ anabolic agents) if started $12 weeks and $30 days
prior to study entry, respectively. Race and ethnicity were self-
reported by study subjects and categorized as per National
Institutes of Health guidelines.
Ethics
The study protocol was approved by the institutional review
boards of all participating study sites (Weill Cornell Medical
College Institutional Review Board, Columbia University Medical
Center Institutional Review Board, St. Luke’s-Roosevelt Institu-
tional Review Board, and Western Institutional Review Board).
All subjects provided written informed consent.
Study Interventions and Assessments
Subjects self-administered rhGH 3 mg or matching saline
placebo (SerostimH, EMD Serono, Rockland, MA) subcutaneously
every evening and rosiglitazone (AvandiaH, GlaxoSmithKline,
Research Triangle Park, NC) 4 mg or matching placebo orally
twice daily. The rhGH dose was based on demonstrated efficacy at
reducing visceral fat in a previously published pilot study [17].
Subjects were asked to continue their usual diets and exercise
routines throughout the study.
A 50% dose reduction of rhGH/placebo after initial interrup-
tion of treatment for up to 7 days was permitted to manage severe
hyperglycemia (fasting glucose .7.77 mmol/L [140 mg/dL] or 2-
hour OGTT glucose .13.3 mmol/L [240 mg/dL]), marked
hypertension (symptomatic or $blood pressure 200/110 mmHg),
fasting trigylcerides .20.3 mmol/L (1,800 mg/dL), or severe
paresthesias. A 50% reduction of rhGH/placebo without inter-
ruption of treatment was permitted for moderate hyperglycemia
(fasting glucose .6.99 mmol/L (126 mg/dL) and ,7.77 mmol/L
or 2-hour OGTT glucose .11.1 mmol/L (200 mg/dL) and
,13.3 mmol/L, asymptomatic hypertension (blood pressure
140/90 to 200/110 mmHg), intolerable tissue turgor or arthral-
gias, fasting triglycerides 13.6 mmol/L (1200 mg/dL) to
20.30 mmol/L (1800 mg/dL),or symptoms of carpal tunnel
syndrome. Sustained fasting glucose .6.99 mmol/L resulted in
permanent discontinuation of rhGH/placebo. Subjects with
peripheral edema were managed in a step-wise fashion: (1)
counseled to reduce dietary sodium; (2) prescribed a low dose of
diuretic; (3) reduced rhGH by 50%; (4) reduced rosiglitazone by
50%.
Study visits were scheduled at screening, pre-entry, entry, and
weeks 2, 4, 6, 8, and 12 of the double-blind phase. Fasting labs and
a two-hour OGTT were obtained at screening to determine
eligibility. Anthropometric measurements were done in triplicate
and averaged by trained staff using a Gulick II tape measure with
tensiometer. Waist circumference was measured in the horizontal
plane at a point immediately below the anterior part of the lowest
ribs. Hip circumference was defined as the largest measurable
circumference in the horizontal plane at a point between the iliac
crest and greater trochanter. Eligible subjects underwent body
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composition testing in the fasted state on day 1 of entry and were
admitted to one of three inpatient clinical research centers
afterwards for performance of metabolic assessments the following
morning. Body composition assessments consisted of whole body
MRI and DEXA scanning as described previously [7] and
measurement of total body and extracellular water volumes by
isotope dilution. On day 2 of entry, subjects underwent a three
hour insulin-modified FSIVGTT in the fasted state [18]. Samples
for glucose and insulin determination were collected at 220, 215,
210, 25, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 9, 22, 24, 25, 27, 30, 40,
50, 60, 90, 100, 120, 140, 160, and 180 minutes. At time 0,
300 mg/kg of glucose (50% dextrose) was administered by
intravenous bolus followed by 0.03 U/kg of insulin at the
20 minute time point. Insulin sensitivity (SI) was calculated using
MinMod software (Millennium, version 6.02, 3/29/04) [19].
Entry assessments were repeated at week 12. Subjects underwent
two hour 75 g OGTTs at weeks 4 and 11 and routine safety
laboratory testing at weeks 2, 4, 6, 8, and 12. Impaired fasting
glucose was defined as a fasting glucose level of 5.6–6.9 mmol/L;
impaired glucose tolerance as a 2-hour glucose value of 7.8–
11.0 mmol/L; and, diabetes mellitus as a fasting glucose of
$7.0 mmol/L or 2-hour value of $11.1 mmol/L. Forty-two
subjects underwent assessments of basal lipolytic rate immediately
prior to the FSIVGTT (data not reported herein).
Insulin and insulin were assayed in bulk on stored frozen samples
at the New York Obesity Research Center Core Laboratory, St.
Luke’s-Roosevelt Hospital Center. Insulin was assayed using a
commercial 125I labeling radioimmunoassay (Human insulin RIA
kit, Linco Research, Inc. St. Charles, MO) and glucose was assayed
using a Beckman Glucose Analyzer (Beckman Coulter, Fullerton,
CA). The inter-assay coefficients of variation for assays of plasma
insulin and glucose were 6% and ,3%, respectively. Fasting lipids
were measured by standard enzymatic methods. Serum concentra-
tion of IGF-1 was determined in the General Core Laboratory of
the Weill Cornell Clinical and Translational Science Center using a
quantitative sandwich enzyme immunoassay kit (R&D Systems,
Inc., Minneapolis, MN) following the manufacturer’s instructions.
The intra-assay coefficient of variation is 3.5%–4.3%, and the inter-
assay coefficient of variation is 7.5%–8.3%. The sensitivity of the
assay is 0.026 ng/mL.
Body Composition Methods
MRI. Whole body Magnetic Resonance Imaging (MRI) scans
were performed using a 1.5 T system (Signa LX version 10; GE
Medical Systems, Milwaukee) using a previously validated
research protocol [7,14]. Subjects lay supine with arms extended
above their heads and were scanned in two segments with a
common landmark at the L4–L5 inter-vertebral space. The spin-
echo sequence had a 200 ms repetition time and a 14 ms echo
time and acquired approximately 40 axial T1-weighted images
with 10-mm thickness at 40-mm intervals from fingers to toes. The
MRI images were analyzed by a single analyst (QH) using research
image analysis software (SliceOmatic, version 4.0; Tomovision
Inc, Montreal). Whole body adipose tissue was first segmented into
visceral adipose tissue (VAT) and subcutaneous adipose tissue
(SAT) compartments. Adipose tissue volumes were calculated
according to the following formula: V =S(T+I)6Si, where T and I
are slice thickness and inter-slice interval respectively, and Si is the
area of the tissue of interest on an individual image slice.
DEXA. Total body fat and total body fat-free mass were
assessed using DEXA as previously described [7,14]. The DEXA
scanner (Lunar DPX, Lunar Radiation Corp., Madison WI) scans
the whole body using an X-ray tube operating at two known X-ray
energy levels. The scanner and system software calculate the
attenuation of the different energy sources as they are absorbed by
fat-free mass and lower density fat mass. Patients lay supine on the
scanning table, positioned beneath the scanning arm, with
transverse head-to-toe scans collected at 1.0 cm intervals.
Total Body Water (TBW) and Extracellular Water
(ECW). Assessment of TBW and ECW was determined by
tracer dilution using deuterated water and sodium bromide,
respectively. A baseline pre-tracer plasma sample was drawn
followed by oral dosing of deuterium oxide and sodium bromide.
An equilibrium plasma sample was obtained at steady state
conditions three hours after dose administration. Samples were
analyzed by infrared spectrophotometry to determine TBW [20]
and liquid chromatography to determine ECW [21]. The
reproducibility of the TBW and ECW tests are 61% and
61.3% respectively in the body composition laboratory.
Sample Size
Since no pertinent data were available on SI by FSIVGTT with
the interventions under study in this patient population, the
sample size calculation was based on changes in insulin-stimulated
glucose uptake by euglycemic hyperinsulinemic clamp in separate
studies of HIV-infected subjects receiving rhGH 3 mg daily (data
from week 4) [17] and rosiglitazone 4 mg twice daily (data from
week 12) [22]. Details of the sample size calculation are provided
in Appendix S1. Twenty subjects per arm with a premature
discontinuation rate of 20% (i.e. 16 completers per arm) resulted in
the following estimates of power: 39–99% for the rhGH main
effect, 95–99% for the rosiglitazone main effect, and 5–94% for
the interaction. We also performed an a priori power calculation
for change in VAT at week 12 based on an estimated 1.25 L
reduction in VAT with rhGH and 20.5 L reduction with
rosiglitazone and no interaction. With 16 evaluable subjects per
arm, we had 99% power for the rhGH main effect, 69% for
rosiglitazone, and 69% for the interaction.
Randomization—Sequence Generation
The randomization sequence was generated in SAS (SAS
Institute Inc., Cary, NC) by a study statistician and provided to the
research pharmacist. Randomization was stratified on study site
and presence or absence of impaired glucose tolerance and used
permuted blocks of four.
Randomization—Allocation Concealment and
Implementation
Study site personnel entered subject information into a
customized, web-based electronic case report system, which
generated sequential study numbers coded by study site and
presence or absence of impaired glucose tolerance. The system
generated a randomization sheet that was faxed to the central
research pharmacy. The study pharmacist, who had no contact
with the study subjects, determined the treatment assignment
based on the randomization sequence and dispensed the
appropriate study drugs. All treatment assignments were verified
by a study statistician prior to dispensing study drugs. The
allocation sequence was concealed from the researchers enrolling
and assessing participants as only the central research pharmacist
and statistician, neither of whom had contact with the participants,
had access to the randomization list.
Blinding
Study subjects and all study personnel were blinded to group
assignments. Only the research pharmacist and study statistician
had access to information about group assignment.
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Statistical Methods
Baseline data were summarized on all randomized subjects.
Subjects who never initiated study drugs were excluded from
safety and efficacy analyses. Given that the study focused on the
physiologic effects of the interventions, analyses of changes from
baseline to week 12 of metabolic or body composition parameters
included only subjects with complete data at both time points;
missing data were not imputed. Changes in dose or discontinu-
ations of study drugs, however, were disregarded, and subjects
were counted as if they continued on their randomized treatment
as would be done in an intention to treat analysis. The mean and
standard deviation (SD) for continuous variables were calculated at
baseline and change at week 12 by study arm. Frequency and
percentages are reported for categorical variables. The correla-
tions between two continuous variables were calculated by Pearson
correlation coefficient. The Jonckheere-Terpstra non-parametric
test was used to test for differences between treatment arms and
ordered categorical outcomes of glucose tolerance. One-way
Analysis of Covariance (ANCOVA) was used to evaluate
treatment effects on primary and secondary endpoints, and
Dunnett-Hsu adjustment was used for post-hoc pair-wise com-
parisons to the double placebo arm. In addition, two-way
ANCOVA was performed to evaluate the interaction of
rosiglitazone and rhGH. We adjusted for the corresponding
baseline values in all regression models with the endpoints of
change at week 12 as outcomes. Normality of residuals from one-
way and two-way ANCOVA were tested through the Kolmo-
gorov-Smirnov test. If normality of residuals failed, the ANCOVA
analysis was based on rank-transformed data [23], and median
and first and third quartiles (Q1, Q3) of the original scale data
were reported. The number of incident adverse events was
tabulated using the maximum of relationship to treatment or
severity for each subject. All p-values were two-sided, and p,0.05
was considered as statistical significance. Analyses were conducted
with SAS software, version 9.2 (SAS Institute, Cary, NC).
The study was monitored by an independent Data and Safety
Monitoring Board that reviewed accrual, data completeness, and
adverse event data by blinded study arm. No efficacy data were
reviewed, and no statistical testing was done for the interim safety
reviews.
Results
Disposition of Subjects and Baseline Characteristics
From February 2005 to December 2009, we screened 127 subjects,
of whom 77 were randomized (Figure 1) [24]. The most common
reasons for screen failure were QUICKI.0.33 (n = 6), withdrawal of
consent or loss to follow-up (n = 7), and 2-hour glucose on
OGTT.11.1 mmol/L (n = 5). Of the 77 randomized subjects, 5
withdrew consent prior to initiating study drug. Rates of completion of
week 12 of the study were 22/22 on rosiglitazone/rhGH, 17/18 on
rosiglitazone, 13/15 on rhGH, and 17/17 on double placebo.
Table 1 summarizes the baseline characteristics of all random-
ized subjects (n = 77); characteristics were similar when restricted
to the 72 subjects who initiated study drugs Overall, the mean age
was 47.9 (7.1), 77.9% were men, 31.2% were black, and 39.0%
Hispanic. Most subjects were on protease inhibitor or non-
nucleoside reverse transcriptase inhibitor based regimens, and
29.9% were receiving thymidine analogues. The mean CD4 count
was 579 (255)6106 cells/L and 66.2% had suppressed HIV viral
loads. Use of testosterone supplementation, lipid-lowering therapy,
and anti-hypertensives was common. Overall, the mean BMI was
29.1 (4.4) kg/m2, waist circumference 103.7 (9.88) cm, and
waist:hip ratio 1.04 (0.06).
Adverse Events
Table 2 summarizes treatment emergent adverse events by
study arm. The numbers of adverse events considered possibly/
probably related to study drug(s)/placebo(s) were: 17 in the
rosiglitazone/rhGH arm (6 resulting in dose reduction of rhGH
and 0 in drug discontinuation); 11 in the rosiglitazone arm (2
resulting in dose reduction of rhGH placebo and 0 in drug
discontinuation); 14 in the rhGH arm (4 resulting in dose
reduction of rhGH and 2 in rhGH discontinuation); and 9 in
the double placebo arm (none resulting in dose reduction or drug
discontinuation). The most common adverse events were edema
and musculoskeletal symptoms/signs, which were seen predomi-
nantly in the rhGH-containing arms.
The cumulative incidence of fasting hyperglycemia reported in
real time as an adverse event by study arm was: 5/22 (including
two grade 3) in the rosiglitazone/rhGH arm, 1/18 (one grade 3) in
the rosiglitazone arm, 8/15 (including three grade 3 and one grade
4) in the rhGH arm, and 2/17 (all,grade 3) in the double placebo
arm. One subject in the rosiglitazone/rhGH arm dose reduced
rhGH due to hyperglycemia; two in the rosiglitazone arm dose
reduced rhGH placebo due to hyperglycemia; and two in the
rhGH arm discontinued rhGH and one dose reduced rhGH due
to hyperglycemia. There were no serious adverse events consid-
ered to be possibly, probably, or definitely related to study drugs.
Insulin Sensitivity and Glucose Tolerance
By FSIVGTT, the change in SI from entry to week 12 differed
significantly across the 4 arms by 1-way ANCOVA on rank-
transformed data (P = 0.0002; Table 3); by pair-wise comparisons
relative to the double placebo arm, SI decreased significantly in
the rhGH arm (P = 0.02). There was no significant rhGH x
rosiglitazone interaction for change in SI by 2-way ANCOVA
(P = 0.97); pooling across arms, the rhGH main effect (decreasing
SI; P,.0001) and rosiglitazone main effect (increasing SI;
P = 0.003) were statistically significant.
Change in fasting glucose from entry to week 12 differed across
arms, driven by a statistically significant increase of 0.86 mmol/L
in the rhGH alone arm (P = 0.014). The rosiglitazone x rhGH
interaction for change in fasting glucose was statistically significant
(P = 0.039). Fasting insulin and insulin area under the curve on
OGTT did not change significantly across the study arms. Change
in glucose area under the curve on OGTT from entry to week 12
differed across arms (1-way ANCOVA P = 0.004), increasing in
the rhGH arm relative to double placebo (P = 0.026) but not
differing in the other arms. By 2-way ANCOVA, the rhGH x
rosiglitazone interaction was borderline significant (P = 0.094).
Figure 2 summarizes changes in glucose tolerance categories
over time by study arm. Six of 22 (27%) on rosiglitazone/rhGH, 3
of 17 (18%) on rosiglitazone alone, 6 of 13 (46%) on rhGH alone,
and 4 of 15 (27%) on double placebo shifted OGTT categories
adversely at week 12 (P = 0.84, exact Jonckheere-Terpstra test).
Specifically, in the rosiglitazone/rhGH arm one subject with
normal glucose tolerance at entry and one with impaired glucose
tolerance were diabetic at week 12. In the rosiglitazone alone arm,
one subject with normal glucose tolerance was diabetic at week 12.
In the rhGH alone arm, two with normal glucose tolerance were
diabetic at week 12. Of note, two other subjects in the rhGH arm
who qualified for the study based on screening fasting glucose and
2-hour glucose values on OGTT done at the local laboratories in
real time met criteria for diabetes mellitus retrospectively on
batched testing of stored OGTT samples and remained classified
as diabetic at week 12. Similarly, one subject each in the
rosiglitazone/rhGH arm and the rosiglitazone arm was diabetic at
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entry and had impaired glucose tolerance at week 12. In the double
placebo arm, no subjects were classified as diabetic at week 12.
Body Composition
Table 4 summarizes changes in body composition by whole
body MRI scan. VAT decreased significantly from baseline in the
rosiglitazone/rhGH and rhGH arms compared to placebo
(217.5% and 222.7% versus 21.87%, respectively) but did not
change significantly in the rosiglitazone arm (22.5%). There was
no significant rhGH x rosiglitazone interaction for change in VAT
by 2-way ANCOVA (P = 0.70); pooling across arms, the rhGH
main effect (decreasing VAT; P = 0.0001) but not rosiglitazone
main effect (P = 0.69) was statistically significant. There were no
statistically significant changes across the arms in SAT or TAT by
Figure 1. CONSORT Flow Diagram.
doi:10.1371/journal.pone.0061160.g001
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one-way ANCOVA. Neither the interaction terms nor the main
effects were statistically significant in the two-way ANCOVA
models for SAT and TAT. The change in skeletal muscle volume
was statistically significant across the four arms by 1-way
ANCOVA (P = 0.014), with trends for modest increases in the
rhGH-containing arms (rosiglitazone/rhGH 4.72% and rhGH
6.71%). By 2-way ANCOVA, the rhGH main effect on skeletal
muscle volume was statistically significant (P = 0.0071) but not the
rosiglitazone main effect (P = 0.68). Overall, change in VAT did
not correlate with change in SI (r = 0.0097; P = 0.94).
Data on changes in body composition by DEXA and stable
isotope dilution are summarized in Table S1. Body weight did not
change significantly across the study arms. Total and trunk fat
tended to decrease in the rhGH-containing arms (210.7% and
212.8% in the rosiglitazone/rhGH and 28.78% and 211.9%
rhGH arms, respectively), though not achieving statistical significance
from one-way ANCOVA. Lean body mass increased significantly in
the rhGH-containing arms (5.97% and 4.58% in the rosiglitazone/
rhGH and in the rhGH arms, respectively). Limb fat changed
significantly across study arms (P = 0.026); pair-wise comparisons
were statistically significant only for the comparison of rosiglitazone
alone (+8.8%) to placebo (P = 0.044). By 2-way ANCOVA, the rhGH
x rosiglitazone interaction was borderline significant (P = 0.069),
suggestive of rhGH antagonizing the effect of rosiglitazone on
increasing limb fat. Total body water and extracellular water volumes
did not change significantly across study arms.
Insulin-Like Growth Factor-1 (IGF-1)
Data on changes in IGF-1 from baseline to week 12 were
available on a subset of subjects who completed week 12













Demographic Age, years 46.8 (9.4) 49.3 (6.1) 48.6 (4.9) 46.6 (6.7)
Sex Male 18 (81.8%) 15 (78.9%) 14 (82.4%) 13 (68.4%)
Race White 15 (68.2%) 11 (57.9%) 11 (64.7%) 12 (63.2%)
Black 6 (27.3%) 6 (31.6%) 6 (35.3%) 6 (31.6%)
.1 race 1 (4.6%) 2 (10.5%) 0 1 (5.3%)
Ethnicity Hispanic 9 (40.9%) 9 (47.4%) 3 (17.6%) 9 (47.4%)
Non-Hispanic 13 (59.1%) 10 (52.6%) 14 (82.4%) 10 (52.6%)
HIV Antiretro-viral regimen $2 NRTIs+NNRTI 7 (31.8%) 7 (36.8%) 8 (47.1%) 7 (36.8%)
$2 NRTIs+PI 11 (50%) 9 (47.4%) 6 (35.3%) 10 (52.6%)
$3 NRTIs 2 (9.1%) 0 2 (11.8%) 0
Other 2 (9.1%) 3 (15.8%) 1 (5.9%) 2 (10.5%)
Stavudine or zidovudine
use
5 (22.7%) 5 (26.3%) 5 (29.4%) 8 (42.1%)
Concomitant
Medications
Testosterone 6 (27.7%) 2 (10.5%) 5 (29.4%) 2 (10.5%)
Atypical antipsychotic 5 (22.7%) 3 (15.8%) 1 (5.9%) 0
Fibrate 3 (13.6%) 2 (10.5%) 3 (17.6%) 3 (15.8%)
Statin 7 (31.8%) 7 (36.8%) 5 (29.4%) 5 (26.3%)
Fish oil 0 1 (5.3%) 0 1 (5.3%)
Antihypertensive 6 (27.3%) 5 (26.3%) 5 (29.4%) 5 (26.3%)
Anthropomet-ric Height, cm 172 (11) 171 (8) 174 (9) 169 (8)
Weight, kg 89.4 (20.0) 78.6 (8.6) 92.0 (11.1) 83.3 (17.0)
Body mass index, kg/m2 30.1 (5.1) 26.9 (3.2) 30.3 (3.3) 28.9 (4.7)
Waist circumference, cm 105.13 (11.48) 99.69 (6.34) 107.48 (8.25) 102.73 (11.1)
Hip circumference, cm 100.22 (7.52) 96.27 (4.76) 103.46 (7.74) 99.4 (10.05)
Waist:hip ratio 1.05 (0.06) 1.04 (0.06) 1.04 (0.05) 1.03 (0.06)
Laboratory Values Fasting insulin, pmol/L 140.4 (50.8) 171.9 (186.3) 152.2 (126.0) 132.0 (65.4)
Fasting glucose, mmol/L 5.05 (0.48) 4.77 (0.42) 5.30 (0.52) 5.18 (0.63)
QUICKI 0.31 (0.01) 0.31 (0.02) 0.31 (0.02) 0.31 (0.02)
CD4 count*, cells 6106/L 555 (272) 595 (251) 56 (245) 617 (271)
HIV RNA,400** copies/ml 17 (77.3%) 14 (82.3%) 12 (75.0%) 8 (53.3%)
Continuous variables are expressed as mean (standard deviation).
*CD4 count available on n = 20, 16, 14, and 13 in rhGH/rosiglitazone, rosiglitazone, rhGH, and double placebo arms respectively.
**HIV RNA data available on n = 22, 17, 16, and 15 in rhGH/rosiglitazone, rosiglitazone, rhGH, and double placebo arms respectively.
Abbreviations: NNRTI, non- nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; QUICKI, quantitative insulin
sensitivity check index.
doi:10.1371/journal.pone.0061160.t001
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evaluations and had available frozen serum. At baseline, IGF-1
concentrations were 107.3637.7 ng/ml (n = 14) in the rhGH/
rosiglitazone arm, 110.0633.2 ng/ml (n = 12) in the rosiglitazone
arm, 100.6623.7 ng/ml (n = 9) in the rhGH arm, and 86.6631.9
(n = 12) ng/ml in the double placebo arm. The changes at week 12
were 189.9% in the rhGH/rosiglitazone arm, 20.90% in the
rosiglitazone arm, 123.6% in the rhGH arm, and 13.4% in the
double placebo arm. By 1-way ANCOVA, these changes differed
across arms (P,0.0001). Pair-wise comparisons yielded significant
differences in the rhGH/rosiglitazone and rhGH arms relative to
double placebo (P,0.001 and P = 0.020, respectively). The rhGH
x rosiglitazone interaction term for change in IGF-1 by 2-way
ANCOVA was not statistically significant (P = 0.13); pooling
across arms, the rhGH main effect (increasing IGF-1; P,0.0001)
but not rosiglitazone main effect (P = 0.44) was statistically
significant.
Lipids
Fasting triglycerides were monitored in real time as a safety
measure (summarized in Table 2). Fasting total cholesterol,
calculated low density lipoprotein-cholesterol, high density lipo-
protein-cholesterol (HDL-C), triglycerides, and calculated non-
HDL-C were determined on the subset of subjects who had
available frozen serum at entry, week 4 and week 12. There were
no statistically significant changes in lipid parameters over time by
study arm (data not shown).
Discussion
In this randomized, double-blind, placebo-controlled trial, HIV-
infected subjects with abdominal obesity and insulin resistance
received rhGH, rosiglitazone, dual therapy, or double placebo for
12 weeks. In keeping with our primary hypothesis, the addition of
rosiglitazone to rhGH abrogated the adverse effects of rhGH on
insulin sensitivity as assessed by FSIVGTT and OGTT without
modifying the favorable effects of rhGH on reducing VAT. There
were also fewer hyperglycemia events in the dual therapy arm
compared to the rhGH alone arm.
Combination therapy was relatively well tolerated in this study.
Despite the potential for rosiglitazone to increase plasma volume,
we found no evidence that edema and musculoskeletal side effects
attributable to fluid retention were exacerbated by the addition of
rosiglitazone to rhGH. Furthermore, we were unable to detect
significant changes in total body water or extracellular water
volumes by isotope dilution methods across the study arms.
Studies to date suggest that growth hormone adversely affects
insulin sensitivity primarily by stimulating lipolysis and increasing
free fatty acid concentrations. Administration of acipimox, a
nicotinic acid derivative that inhibits lipolysis at the level of
hormone-sensitive lipase, to growth hormone-deficient adults
receiving rhGH replacement abrogated the effects of rhGH on
insulin sensitivity [25,26]. Thiazolidinediones have pleiotropic
effects that likely account for their favorable effects on insulin
sensitivity; however, their effects on suppressing lipolysis and
reducing free fatty acid concentrations may play a major role in
this regard [27,28]. These observations provided the biological
rationale for combining rosiglitazone with rhGH in our study.
Ongoing analyses of free fatty acid flux from a subset of our
participants should shed further light on the physiologic effects of
the combination of study drugs since data in humans are limited.
Our study is one of the first in HIV-infected subjects to combine
rhGH with a drug aimed at improving insulin sensitivity. Within
the context of a broader pilot study investigating multiple
strategies to manage altered fat distribution in HIV-infected
subjects, Macallan and colleagues randomly assigned 26 subjects
Figure 2. Changes in glucose homeostasis category by 2-hour oral glucose tolerance test. The trends for shifts in categories were not
statistically different across study arms (P = 0.84, exact Jonckheere-Terpstra test). Abbreviations: DM, diabetes mellitus; IFG, impaired fasting glucose;
IGT, impaired glucose tolerance; NGT, normal glucose tolerance.
doi:10.1371/journal.pone.0061160.g002
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with lipoatrophy, of whom about half had visceral adiposity, to
receive rhGH 2 mg daily or rhGH 2 mg daily plus rosiglitazone
4 mg daily for 12 weeks [29]. Mean fasting plasma insulin
increased and HOMA %S (insulin sensitivity; the reciprocal of
HOMA-insulin resistance) decreased within the rhGH arm but did
not change significantly from baseline within the dual therapy
arm, suggesting a beneficial effect of the addition of rosiglitazone
on glucose homeostasis. Of note, our study population differed
from that of Macallan et al in that all of our subjects had visceral
adiposity, the population for which manipulation of the GH axis
could be beneficial, as well as insulin resistance.
We found that rosiglitazone did not interact with rhGH with
regard to changes in body composition. The thiazolidinedione
drugs have had inconsistent effects on reducing VAT in patients
with diabetes mellitus in the general population [30–34]. In a
randomized, double-blind, placebo-controlled trial with a 262
factorial design, pioglitazone and rhGH (8 mg/kg/d) were studied
in 62 abdominally obese adults [35]. Pioglitazone alone did not
reduce VAT significantly, whereas the combination of rhGH and
pioglitazone reduced VAT similarly to rhGH alone. Studies of
rosiglitazone or pioglitazone for lipoatrophy in HIV-infected
patients, however, have generally not had favorable effects on
VAT. The effects of rosiglitazone and pioglitazone on HIV-
associated lipoatrophy have also been mixed [36,37]. Patients who
were not currently taking thymidine analog reverse transcriptase
inhibitors did gain limb fat with rosiglitazone [13] and
pioglitazone [12] in two studies. Our study subjects were not
selected on the basis of having lipoatrophy, and most were not
currently taking thymidine analogs. Nonetheless, we did not find
significant changes in subcutaneous fat volume by MRI or arm or
leg fat mass by DEXA in the rosiglitazone-containing arms relative
to placebo.
Our study has several strengths, including the randomized,
double-blind design, the use of sensitive, standardized physiolog-
ical and body composition assessments, and the diverse patient
population. The study limitations include the fact that we did not
fully enroll the study and may have been underpowered for the
primary endpoint despite excellent retention of subjects. Due to
slower than expected accrual, there may have been temporal
changes in antiretroviral therapy during the course of the study,
though individual subjects did not change therapy during the
blinded phase of the study. The randomized design, however,
makes it unlikely that inter-arm differences were a source of bias.
Lastly, our study population included subjects who met an
arbitrary definition of insulin resistance, and the results cannot
be generalized to patients with frank diabetes or who do not have
insulin resistance.
Both study drugs have fallen out of favor since the design and
conduct of our study. Growth hormone did not receive approval
by the U.S. Food and Drug Administration (FDA) for the
indication of reducing abdominal fat in HIV-infected subjects
despite efficacy demonstrated in clinical trials [8–10]. In contrast,
tesamorelin, a synthetic analogue of growth hormone releasing
factor, is FDA approved for this indication and has only mild
adverse effects on glucose homeostasis [38–41]. Rosiglitazone is
either not available or restricted in its use in most parts of the
world due to concerns about its potential to increase cardiovas-
cular event rates [42–45]. Nonetheless, our study provides proof of
concept of combining an insulin-sensitizing drug with growth













































































































































































































































































































































































































































































































































































































































































































































































































































































































































Growth Hormone/Rosiglitazone & Visceral Fat in HIV
PLOS ONE | www.plosone.org 10 April 2013 | Volume 8 | Issue 4 | e61160
Supporting Information
Appendix S1 Sample size calculations.
(DOCX)
Checklist S1 CONSORT 2010 checklist of information
to include when reporting a randomised trial.
(DOC)
Protocol S1 Study protocol.
(PDF)
Table S1 Baseline and Change at Week 12 in Body
Weight and Body Composition Parameters by Dual
Energy Absorptiometry and Stable Isotope Dilution.
(DOC)
Acknowledgments
The authors thank Norma Muurahainen for helpful discussions and the
following individuals for their assistance with the conduct of the study:
Yuriy Akulov, Yolanda Barrón, Steven Benkert, Yim Dam, Ben Eckhardt,
Barbra Hormann, Valery Hughes, Vivien Leung, Carol Levy, Jay Luther,
Zaiwei Liu, Janet Sheikhan, Carlos Lopez, Douglas Mendez, Franco
Santiago, Chungkol Subudom, Glenn Sturge, Michael Yin, and Yuan-
Shan Zhu. The authors also gratefully acknowledge the efforts of the Data
and Safety Monitoring Board (Judith Currier [chair], Ann Danoff, and
Morris Schambelan) and thank the dedicated study volunteers.
Author Contributions
Conceived and designed the experiments: MJG JA EE HNG DD ML
DPK. Performed the experiments: MJG JA KH EE DD JE. Analyzed the
data: MJG Y-LC JA QH VM. Wrote the paper: MJG.
References
1. Grinspoon S, Carr A (2005) Cardiovascular risk and body-fat abnormalities in
HIV-infected adults. N Engl J Med 352: 48–62. 352/1/48 [pii];10.1056/
NEJMra041811 [doi].
2. Brown TT, Glesby MJ (2012) Management of the metabolic effects of HIV and
HIV drugs. Nat Rev Endocrinol 8: 11–21. nrendo.2011.151 [pii];10.1038/
nrendo.2011.151 [doi].
3. Brinkman K, Smeitink JA, Romijn JA, Reiss P (1999) Mitochondrial toxicity
induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in
the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 354:
1112–1115.
4. McComsey GA, Kitch D, Sax PE, Tebas P, Tierney C, et al. (2011) Peripheral
and central fat changes in subjects randomized to abacavir-lamivudine or
tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study
A5224s. Clin Infect Dis 53: 185–196. cir324 [pii];10.1093/cid/cir324 [doi].
5. Koutkia P, Canavan B, Breu J, Grinspoon S (2005) Growth hormone (GH)
responses to GH-releasing hormone-arginine testing in human immunodefi-
ciency virus lipodystrophy. J Clin Endocrinol Metab 90: 32–38.
6. Rietschel P, Hadigan C, Corcoran C, Stanley T, Neubauer G, et al. (2001)
Assessment of growth hormone dynamics in human immunodeficiency virus-
related lipodystrophy. J Clin Endocrinol Metab 86: 504–510.
7. Engelson ES, Glesby MJ, Mendez D, Albu JB, Wang J, et al. (2002) Effect of
recombinant human growth hormone in the treatment of visceral fat
accumulation in HIV infection. J Acquir Immune Defic Syndr 30: 379–391.
8. Grunfeld C, Thompson M, Brown SJ, Richmond G, Lee D, et al. (2007)
Recombinant human growth hormone to treat HIV-associated adipose
redistribution syndrome: 12 week induction and 24-week maintenance therapy.
J Acquir Immune Defic Syndr 45: 286–297.
9. Kotler DP, Muurahainen N, Grunfeld C, Wanke C, Thompson M, et al. (2004)
Effects of growth hormone on abnormal visceral adipose tissue accumulation
and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr 35:
239–252.
10. Kotler DP, Muurahainen N, Grunfeld C, Wanke C, Thompson Met al. (2006)
Effects of growth hormone on visceral adipose tissue and dyslipidemia in HIV,
an erratum. J Acquir Immune Defic Syndr 43: 378–380.
11. Adams M, Montague CT, Prins JB, Holder JC, Smith SA, et al. (1997)
Activators of peroxisome proliferator-activated receptor gamma have depot-
specific effects on human preadipocyte differentiation. J Clin Invest 100: 3149–
3153. 10.1172/JCI119870 [doi].
12. Slama L, Lanoy E, Valantin MA, Bastard JP, Chermak A, et al. (2008) Effect of
pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind
placebo-controlled trial (ANRS 113). Antivir Ther 13: 67–76.
13. Tungsiripat M, Bejjani DE, Rizk N, O’Riordan MA, Ross AC, et al. (2010)
Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing
regimens. AIDS 24: 1291–1298. 10.1097/QAD.0b013e328339e274 [doi].
14. Engelson ES, Kotler DP, Tan Y, Agin D, Wang J, et al. (1999) Fat distribution in
HIV-infected patients reporting truncal enlargement quantified by whole-body
magnetic resonance imaging. Am J Clin Nutr 69: 162–169.
15. Molarius A, Seidell JC (1998) Selection of anthropometric indicators for
classification of abdominal fatness–a critical review. Int J Obes Relat Metab
Disord 22: 719–727.
16. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, et al. (2000)
Quantitative insulin sensitivity check index: a simple, accurate method for
assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85: 2402–2410.
17. Lo JC, Mulligan K, Noor MA, Schwarz JM, Halvorsen RA, et al. (2001) The
effects of recombinant human growth hormone on body composition and
glucose metabolism in HIV-infected patients with fat accumulation. J Clin
Endocrinol Metab 86: 3480–3487.
18. Steil GM, Murray J, Bergman RN, Buchanan TA (1994) Repeatability of insulin
sensitivity and glucose effectiveness from the minimal model. Implications for
study design. Diabetes 43: 1365–1371.
19. Boston RC, Stefanovski D, Moate PJ, Sumner AE, Watanabe RM, et al. (2003)
MINMOD Millennium: a computer program to calculate glucose effectiveness
and insulin sensitivity from the frequently sampled intravenous glucose tolerance
test. Diabetes Technol Ther 5: 1003–1015. 10.1089/152091503322641060
[doi].
20. Lukaski HC, Johnson PE (1985) A simple, inexpensive method of determining
total body water using a tracer dose of D2O and infrared absorption of
biological fluids. Am J Clin Nutr 41: 363–370.
21. Wong WW, Sheng HP, Morkeberg JC, Kosanovich JL, Clarke LL, et al. (1989)
Measurement of extracellular water volume by bromide ion chromatography.
Am J Clin Nutr 50: 1290–1294.
22. Gelato MC, Mynarcik DC, Quick JL, Steigbigel RT, Fuhrer J, et al. (2002)
Improved insulin sensitivity and body fat distribution in HIV-infected patients
treated with rosiglitazone: a pilot study. J Acquir Immune Defic Syndr 31: 163–
170.
23. Iman R (1982) Some Aspects of the Rank Transformation in Analysis of
Variance Problems. Proceedings of the SAS User’s Group Intl 7: 676–680.
24. Schulz KF, Altman DG, Moher D (2010) CONSORT 2010 statement: updated
guidelines for reporting parallel group randomised trials. PLoS Med 7:
e1000251. 10.1371/journal.pmed.1000251 [doi].
25. Nielsen S, Moller N, Christiansen JS, Jorgensen JO (2001) Pharmacological
antilipolysis restores insulin sensitivity during growth hormone exposure.
Diabetes 50: 2301–2308.
26. Segerlantz M, Bramnert M, Manhem P, Laurila E, Groop LC (2001) Inhibition
of the rise in FFA by Acipimox partially prevents GH-induced insulin resistance
in GH-deficient adults. J Clin Endocrinol Metab 86: 5813–5818.
27. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, et al. (2002) The
effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal
muscle triglyceride content in patients with type 2 diabetes. Diabetes 51: 797–
802.
28. Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, et al. (2001) Effect of
rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II
diabetic patients. Diabetologia 44: 2210–2219.
29. Macallan DC, Baldwin C, Mandalia S, Pandol-Kaljevic V, Higgins N, et al.
(2008) Treatment of altered body composition in HIV-associated lipodystrophy:
comparison of rosiglitazone, pravastatin, and recombinant human growth
hormone. HIV Clin Trials 9: 254–268. C71241628474U500 [pii];10.1310/
hct0904-254 [doi].
30. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, et al. (2002)
Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type
2 diabetic patients. J Clin Endocrinol Metab 87: 2784–2791.
31. Mori Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, et al. (1999) Effect
of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care
22: 908–912.
32. Kawai T, Takei I, Oguma Y, Ohashi N, Tokui M, et al. (1999) Effects of
troglitazone on fat distribution in the treatment of male type 2 diabetes.
Metabolism 48: 1102–1107.
33. Nakamura T, Funahashi T, Yamashita S, Nishida M, Nishida Y, et al. (2001)
Thiazolidinedione derivative improves fat distribution and multiple risk factors
in subjects with visceral fat accumulation–double-blind placebo-controlled trial.
Diabetes Res Clin Pract 54: 181–190.
34. Smith SR, de JL, Volaufova J, Li Y, Xie H, et al. (2005) Effect of pioglitazone on
body composition and energy expenditure: a randomized controlled trial.
Metabolism 54: 24–32. S0026049504003026 [pii].
35. Attallah H, Friedlander AL, Nino-Murcia M, Hoffman AR (2007) Effects of
growth hormone and pioglitazone in viscerally obese adults with impaired
glucose tolerance: a factorial clinical trial. PLoS Clin Trials 2: e21. 10.1371/
journal.pctr.0020021 [doi].
36. Sheth SH, Larson RJ (2010) The efficacy and safety of insulin-sensitizing drugs
in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials.
Growth Hormone/Rosiglitazone & Visceral Fat in HIV
PLOS ONE | www.plosone.org 11 April 2013 | Volume 8 | Issue 4 | e61160
BMC Infect Dis 10: 183. 1471-2334-10-183 [pii];10.1186/1471-2334-10-183
[doi].
37. Raboud JM, Diong C, Carr A, Grinspoon S, Mulligan K, et al. (2010) A meta-
analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV
lipoatrophy. HIV Clin Trials 11: 39–50. J11410W13135W7W2 [pii];10.1310/
hct1101-39 [doi].
38. Falutz J, Allas S, Kotler D, Thompson M, Koutkia P, et al. (2005) A placebo-
controlled, dose-ranging study of a growth hormone releasing factor in HIV-
infected patients with abdominal fat accumulation. AIDS 19: 1279–1287.
39. Falutz J, Allas S, Blot K, Potvin D, Kotler D, et al. (2007) Metabolic effects of a
growth hormone-releasing factor in patients with HIV. N Engl J Med 357:
2359–2370.
40. Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, et al. (2010) Effects of
tesamorelin (TH9507), a growth hormone-releasing factor analog, in human
immunodeficiency virus-infected patients with excess abdominal fat: a pooled
analysis of two multicenter, double-blind placebo-controlled phase 3 trials with
safety extension data. J Clin Endocrinol Metab 95: 4291–4304. jc.2010-0490
[pii];10.1210/jc.2010-0490 [doi].
41. Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, et al. (2010) Effects of
tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with
abdominal fat accumulation: a randomized placebo-controlled trial with a safety
extension. J Acquir Immune Defic Syndr 53: 311–322. 10.1097/QAI.0-
b013e3181cbdaff [doi].
42. Bourg CA, Phillips BB (2012) Rosiglitazone, myocardial ischemic risk, and
recent regulatory actions. Ann Pharmacother 46: 282–289. aph.1Q400
[pii];10.1345/aph.1Q400 [doi].
43. Nissen SE, Wolski K (2010) Rosiglitazone revisited: an updated meta-analysis of
risk for myocardial infarction and cardiovascular mortality. Arch Intern Med
170: 1191–1201. 2010.207 [pii];10.1001/archinternmed.2010.207 [doi].
44. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial
infarction and death from cardiovascular causes. N Engl J Med 356: 2457–2471.
NEJMoa072761 [pii];10.1056/NEJMoa072761 [doi].
45. Singh S, Loke YK, Furberg CD (2007) Long-term risk of cardiovascular events
with rosiglitazone: a meta-analysis. JAMA 298: 1189–1195. 298/10/1189
[pii];10.1001/jama.298.10.1189 [doi].
Growth Hormone/Rosiglitazone & Visceral Fat in HIV
PLOS ONE | www.plosone.org 12 April 2013 | Volume 8 | Issue 4 | e61160
